HOME >> MEDICINE >> NEWS
Common osteoporosis treatment may help men with prostate cancer suffering from bone loss

SAN FRANCISCO, Feb. 25 Men with prostate cancer who experience bone loss from cancer treatment could benefit from a weekly oral therapy commonly given to women with osteoporosis, according to a study presented by the University of Pittsburgh Medical Center (UPMC) at the American Society of Clinical Oncology Prostate Cancer Symposium, Feb. 24 to 26 at the San Francisco Marriott. The study, abstract number 139, will be featured in a press program at the meeting, 7:30 a.m., Sunday, Feb. 26.

"In previous studies, we have determined that men who receive androgen deprivation therapy, a frequently used treatment for prostate cancer, suffer from severe drops in bone mass and are at an increased risk for fracture," said study principal investigator Susan Greenspan, M.D., professor of medicine, University of Pittsburgh and director, Osteoporosis Prevention and Treatment Center, UPMC. "In an attempt to mitigate these effects, we gave men using this therapy a once-weekly oral agent called alendronate that is commonly used to treat osteoporosis. We found that men who received it had significantly increased bone mass compared to those who did not receive the therapy."

The study included 112 men with prostate cancer with an average age of 71. After an average of two years androgen deprivation therapy for prostate cancer, only 9 percent of the men had normal bone mass, while 52 percent had low bone mass and 39 percent developed osteoporosis. To study the effect of alendronate on these men, they were randomized into two groups to receive either alendronate once a week through an orally administered pill or a placebo. At one year follow-up, bone mass in the spine and hip increased significantly in the men treated with alendronate, 4.9 percent and 2.1 percent respectively. By comparison, men in the placebo group had significant losses of bone mass in the spine and hip, 1.3 percent and .7 percent respectively. In addition, the therapy was well-tolerated and easily adm
'"/>


25-Feb-2006


Page: 1 2

Related medicine news :

1. Commonly used drug offers promise for premature babies
2. Commonly used pain medications do not prevent Alzheimers disease
3. Common anesthetic may induce cell death, generation of Alzheimers-associated protein
4. Common blood pressure drug treats muscular dystrophy in mice
5. Common PTSD drug is no more effective than placebo
6. Common cold may be just a fingertip away due to environmental contamination
7. Commonwealth Fund commission says the US health care system needs thorough transformation
8. Commonly recommended sedative does not improve infant sleep
9. Common asthma inhaler causing deaths, researchers assert
10. Common painkillers associated with increased risk of first hospital admission for heart failure
11. Commonly used blood pressure medication prevents aortic aneurysm in mice with Marfan syndrome

Post Your Comments:
(Date:11/22/2014)... 22, 2014 Setria® Glutathione is ... approved it for use “as a therapeutically active ... within the Therapeutic Goods (Listing) Notice 2014 (No. ... Hakko’s Setria® Glutathione will be exclusivity distributed in ... sources and imports fine chemicals to Australian manufacturers. ...
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that ... developed Type 2 diabetes due to its use continue ... underway in U.S. District Court, District of South Carolina, ... litigation will convene its next Status Conference on December ... Counsel for Plaintiffs and Defendants to meet and confer, ...
(Date:11/22/2014)... November 22, 2014 The Sports Conflict ... Roy Baroff to its team of conflict resolution professionals. ... player, coach, and referee. He has over 30 years experience ... beyond. , “I'm very excited to connect with SCI and ... related interests to a program with a complete sports focus,” ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Wright & ... AndroGel side-effects lawsuits have been scheduled between October ... Northern District of Illinois. U.S. District Judge Matthew F. ... a Case Management Order (CMO) on November 6, 2014 ... for attorneys to submit documents and other activities in ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
(Date:11/22/2014)... 2014 Many power shifts are occurring ... of patients in the biopharmaceutical market is impacting ... than ever, understanding how to effectively acquire, convert, ... essential. According to recent research ... spent about two-thirds of their patient-focused dollars on ...
(Date:11/21/2014)... Nov. 21, 2014 In September 2014, the ... carried out a new product development plan that started ... "limited edition" lab coat , aptly named "Vera ... surgery in the world. The new women,s designer lab ... with a sleek envelope collar, vertical princess and high ...
(Date:11/21/2014)... , Nov. 21, 2014  PTC Therapeutics, Inc. (NASDAQ: ... 2014 Legend of Technology Award for Vision, Innovation, and Leadership ... Chief Executive Officer. This award recognizes an individual who has ... New Jersey for several decades. ... Award," stated Stuart Peltz , Ph.D., CEO of PTC ...
Breaking Medicine Technology:New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
Cached News: